Literature DB >> 15227507

Current treatment of dilated cardiomyopathy.

E K Massin1.   

Abstract

Within the last decade, the treatment for patients with dilated cardiomyopathy has changed. Clinical management of these patients is aimed at controlling congestive heart failure, treating arrhythmias, preventing pulmonary and systemic emboli, and managing chest pain. The goals of treatment for patients with dilated cardiomyopathy are to make the patient feel better and live longer. To achieve this, we direct treatment to improving left ventricular function and cardiac output and controlling arrhythmias and thromboemboli. Basic treatment begins with inotropic therapy, preload reduction, and afterload reduction. For patients with symptomatic disease, we recommend diuretics, digoxin, and converting enzyme inhibitors for first-line therapy. Patients with arrhythmias may be treated by the addition of amiodarone, a pacemaker, or an automatic implantable cardioverter-defibrillator; and most such patients need to be anticoagulated. All patients need close follow-up for possible drug toxicity associated with their regimens. Heart transplantation can be considered for patients refractory to medical treatment. Although the incidence of dilated cardiomyopathy continues to increase, we are learning better ways to treat it. In the future, new drugs with fewer side effects should be available to treat, and perhaps impede, the development of dilated cardiomyopathy.

Entities:  

Year:  1991        PMID: 15227507      PMCID: PMC324959     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  34 in total

1.  SODIUM DIURESIS PRODUCED BY DOPAMINE IN PATIENTS WITH CONGESTIVE HEART FAILURE.

Authors:  L I GOLDBERG; R H MCDONALD; A M ZIMMERMAN
Journal:  N Engl J Med       Date:  1963-11-14       Impact factor: 91.245

2.  Cardiovascular collagenosis with parietal endocardial thrombosis; a clinicopathologic study of forty cases.

Authors:  B J P BECKER; C B CHATGIDAKIS; B VAN LINGEN
Journal:  Circulation       Date:  1953-03       Impact factor: 29.690

3.  Conditioning effects of chronic infusions of dobutamine. Comparison with exercise training.

Authors:  C Liang; R R Tuttle; W B Hood; H Gavras
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

4.  Pharmacological actions of various inotropic agents.

Authors:  H Scholz
Journal:  Eur Heart J       Date:  1983-01       Impact factor: 29.983

5.  Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure.

Authors:  B Kramer; N Topic; B Massie
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Cell-mediated cytotoxicity to cardiac cells of lymphocytes from patients with primary myocardial disease.

Authors:  B Jacobs; Y Matsuda; S Deodhar; E Shirey
Journal:  Am J Clin Pathol       Date:  1979-07       Impact factor: 2.493

7.  Improvement of human myocardial mitochondria after dobutamine: a quantitative ultrastructural study.

Authors:  D V Unverferth; C V Leier; R D Magorien; R Croskery; J R Svirbely; A J Kolibash; M R Dick; J A Meacham; N Baba
Journal:  J Pharmacol Exp Ther       Date:  1980-11       Impact factor: 4.030

8.  One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial.

Authors:  V Hansteen; E Møinichen; E Lorentsen; A Andersen; O Strøm; K Søiland; D Dyrbekk; A M Refsum; A Tromsdal; K Knudsen; C Eika; J Bakken; P Smith; P I Hoff
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-16

9.  Heart failure in outpatients: a randomized trial of digoxin versus placebo.

Authors:  D C Lee; R A Johnson; J B Bingham; M Leahy; R E Dinsmore; A H Goroll; J B Newell; H W Strauss; E Haber
Journal:  N Engl J Med       Date:  1982-03-25       Impact factor: 91.245

10.  Long-term digitalis therapy improves left ventricular function in heart failure.

Authors:  S B Arnold; R C Byrd; W Meister; K Melmon; M D Cheitlin; J D Bristow; W W Parmley; K Chatterjee
Journal:  N Engl J Med       Date:  1980-12-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.